CD72 nanoCARs for the treatment of refractory pediatric B-cell acute lymphoblastic leukemia

  • Post author:
  • Post category:

Translational Candidate CD72-targeting chimeric antigen receptor (CAR) T cells incorporating fully synthetic nanobodies Area of Impact Pediatric B-cell acute lymphoblastic leukemia refractory to currently available treatments without other potentially curative…

Continue ReadingCD72 nanoCARs for the treatment of refractory pediatric B-cell acute lymphoblastic leukemia

Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma

  • Post author:
  • Post category:

Translational Candidate Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Area of Impact Glioblastoma is the most common malignant brain tumor, affecting approximately…

Continue ReadingDevelopment of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma

Clinical Translation of Allogenic Regenerative Cell Therapy for White Matter Stroke and Vascular Dementia

  • Post author:
  • Post category:

Translational Candidate Human induced pluripotent stem cell-derived glial enriched progenitors Area of Impact Vascular dementia and white matter stroke, addressing a current bottleneck of poor scale up for existing cell…

Continue ReadingClinical Translation of Allogenic Regenerative Cell Therapy for White Matter Stroke and Vascular Dementia

Clinical Translation of hESC-derived protein therapy that positively regulates the regenerative capacity of post-natal muscle for treating DM1 

  • Post author:
  • Post category:

Translational Candidate We engineered a human embryonic stem cell-secreted signaling protein into a biologic for treatment of skeletal muscle disorders. Area of Impact Skeletal muscle disorders (including DM1 and sarcopenia)…

Continue ReadingClinical Translation of hESC-derived protein therapy that positively regulates the regenerative capacity of post-natal muscle for treating DM1